13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001937964
Total reported value
$541.9M
$541.9M
32 檔
47.2%
As reported in its official Q1 2025 Form 13F filing, Artia Global Partners LP's tracked investment portfolio stood at $541.9M with 32 total positions.
In Q1 2025, Artia Global Partners LP adopted a defensive or profit-taking posture, trimming 8 positions and completely liquidating 11 holdings to manage risk exposure.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | LLY | Eli Lilly & Co | Stock-Healthcare | 29.24% | -7.04% | EXIT | |
| 2 | SLNOEUR | Soleno Therapeutics Inc | Stock-Other | 13.30% | -0.46% | EXIT | |
| 3 | VRNA | Verona Pharma PLC - Adr | Stock-Other | 8.65% | — | +110.91% | |
| 4 | ITCIEUR | Intra-cellular Therapies Inc | Stock-Other | 7.34% | — | — | |
| 5 | INSM | Insmed Inc | Stock-Healthcare | 6.14% | -18.15% | +89.50% | |
| 6 | ✓ | Merus N V | Stock-Other | 4.52% | — | -8.45% | |
| 7 | PTGX | Protagonist Therapeutics Inc | Stock-Other | 4.09% | +0.04% | +13.61% | |
| 8 | ACLXGBX | Arcellx Inc | Stock-Other | 3.80% | — | -0.30% | |
| 9 | AZNN | Astrazeneca Plc-spons Adr | Stock-Other | 3.55% | — | — | |
| 10 | BSX | Boston Scientific CORP | Stock-Healthcare | 3.31% | — | — | |
| 11 | DGX | Quest Diagnostics Inc | Stock-Healthcare | 2.43% | +0.95% | — | |
| 12 | ALNY | Alnylam Pharmaceuticals Inc | Stock-Healthcare | 1.95% | — | -49.29% | |
| 13 | ARGX | Argenx Se - Adr | Stock-Healthcare | 1.69% | +0.74% | — | |
| 14 | NUVL | Nuvalent Inc-a | Stock-Other | 1.63% | +0.01% | -55.53% | |
| 15 | SRRK | Scholar Rock Holding CORP | Stock-Other | 1.40% | +0.03% | — | |
| 16 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 0.93% | +3.98% | -63.34% | |
| 17 | RYTM | Rhythm Pharmaceuticals Inc | Stock-Other | 0.67% | — | — | |
| 18 | SWTXUSD | Springworks Therapeutics Inc | Stock-Other | 0.60% | — | — | |
| 19 | VKTX | Viking Therapeutics Inc | Stock-Healthcare | 0.55% | +0.12% | — | |
| 20 | VRDN | Viridian Therapeutics Inc | Stock-Other | 0.55% | — | +60.00% | |
| 21 | TGTX | Tg Therapeutics Inc | Stock-Healthcare | 0.54% | — | — | |
| 22 | ISRG | Intuitive Surgical Inc | Stock-Healthcare | 0.44% | — | — | |
| 23 | EYPT | Eyepoint Inc | Stock-Other | 0.43% | +0.04% | +46.15% | |
| 24 | NBIX | Neurocrine Biosciences Inc | Stock-Healthcare | 0.41% | — | -67.33% | |
| 25 | UTHR | United Therapeutics CORP | Stock-Healthcare | 0.39% | -0.09% | — | |
| 26 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 0.34% | -0.04% | — | |
| 27 | ASND | Ascendis Pharma A/S | Stock-Other | 0.29% | -0.81% | EXIT | |
| 28 | JANX | Janux Therapeutics Inc | Stock-Other | 0.26% | — | -76.62% | |
| 29 | MREO | Mereo Biopharma Group Pl-adr | Stock-Other | 0.24% | — | — | |
| 30 | TVTX | Travere Therapeutics Inc | Stock-Other | 0.14% | +3.13% | — | |
| 31 | 260 | Centessa Pharmaceuticals-adr | Stock-Other | 0.13% | — | -56.18% | |
| 32 | ORKA | Oruka Therapeutics Inc | Stock-Other | 0.02% | +0.59% | NEW |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | LLY | Eli Lilly & Co | +29.2% | NEW | New buy |
| 2 | SLNOEUR | Soleno Therapeutics Inc | +5.4% | +48.73% | Add |
| 3 | VRNA | Verona Pharma PLC - Adr | +4.4% | +110.91% | Add |
| 4 | BSX | Boston Scientific CORP | +3.3% | NEW | New buy |
| 5 | DGX | Quest Diagnostics Inc | +2.4% | NEW | New buy |
| 6 | INSM | Insmed Inc | +2% | +89.50% | Add |
| 7 | SRRK | Scholar Rock Holding CORP | +1.4% | NEW | New buy |
| 8 | ITCIEUR | Intra-cellular Therapies Inc | +0.8% | — | Unchanged |
| 9 | ISRG | Intuitive Surgical Inc | +0.4% | NEW | New buy |
| 10 | UTHR | United Therapeutics CORP | +0.4% | NEW | New buy |
| 11 | TVTX | Travere Therapeutics Inc | +0.1% | NEW | New buy |
| 12 | PTGX | Protagonist Therapeutics Inc | 0% | +13.61% | Add |
| 13 | ORKA | Oruka Therapeutics Inc | 0% | NEW | New buy |
| 14 | TGTX | Tg Therapeutics Inc | -0.1% | — | Unchanged |
| 15 | ASND | Ascendis Pharma A/S | -0.1% | — | Unchanged |
| 16 | SWTXUSD | Springworks Therapeutics Inc | -0.1% | — | Unchanged |
| 17 | VRDN | Viridian Therapeutics Inc | -0.1% | +60.00% | Add |
| 18 | EYPT | Eyepoint Inc | -0.2% | +46.15% | Add |
| 19 | XENE | Xenon Pharmaceuticals Inc | -0.2% | — | Unchanged |
| 20 | TECX | Tectonic Therapeutic Inc | -0.3% | EXIT | Sold out |
| 21 | MREO | Mereo Biopharma Group Pl-adr | -0.3% | — | Unchanged |
| 22 | ANNX | Annexon Inc | -0.3% | EXIT | Sold out |
| 23 | RYTM | Rhythm Pharmaceuticals Inc | -0.3% | — | Unchanged |
| 24 | 260 | Centessa Pharmaceuticals-adr | -0.4% | -56.18% | Trim |
| 25 | TARS | Tarsus Pharmaceuticals Inc | -0.4% | EXIT | Sold out |
| 26 | CRL | Charles River Laboratories | -0.4% | EXIT | Sold out |
| 27 | EWTX | Edgewise Therapeutics Inc | -0.5% | EXIT | Sold out |
| 28 | NAMS | NewAmsterdam Pharma Company N.V. | -0.5% | EXIT | Sold out |
| 29 | VKTX | Viking Therapeutics Inc | -0.8% | — | Unchanged |
| 30 | ARGX | Argenx Se - Adr | -0.8% | — | Unchanged |
| 31 | ELVN | Enliven Therapeutics Inc | -0.8% | EXIT | Sold out |
| 32 | CRNX | Crinetics Pharmaceuticals In | -0.8% | EXIT | Sold out |
| 33 | AZNN | Astrazeneca Plc-spons Adr | -0.9% | — | Unchanged |
| 34 | NBIX | Neurocrine Biosciences Inc | -1.8% | -67.33% | Trim |
| 35 | ✓ | Merus N V | -2.5% | -8.45% | Trim |
| 36 | ACLXGBX | Arcellx Inc | -2.5% | -0.30% | Trim |
| 37 | ALNY | Alnylam Pharmaceuticals Inc | -2.8% | -49.29% | Trim |
| 38 | JANX | Janux Therapeutics Inc | -2.9% | -76.62% | Trim |
| 39 | XBI | Ss Spdr S&p Biotech ETF | -3.2% | EXIT | Sold out |
| 40 | RVMD | Revolution Medicines Inc | -3.5% | -63.34% | Trim |
| 41 | NUVL | Nuvalent Inc-a | -4.1% | -55.53% | Trim |
| 42 | PCVX | Vaxcyte Inc | -4.8% | EXIT | Sold out |
| 43 | NVO | Novo-nordisk A/s-spons Adr | -13.8% | EXIT | Sold out |
According to official SEC Form 13F filings, Artia Global Partners LP reported a total U.S. public equity portfolio value of $541.9M across 32 disclosed positions in Q1 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including LLY, SLNOEUR, VRNA) accounted for 47.2% of total reported equity market value during Q1 2025.
Top New Position Initiated
LLY
市值: $115.5M
Top Position Liquidated / Trimmed
NVO
前期市值: $38.7M
During Q1 2025, Artia Global Partners LP's top holdings by market value included LLY (29.2%)、SLNOEUR (13.3%)、VRNA (8.7%). The largest single position, LLY, represented 29.2% of total portfolio value.
In Q1 2025, Artia Global Partners LP made 33 total portfolio adjustments, initiating 8 new buys, adding to 6 positions, trimming 8 holdings, and fully liquidating 11 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.